Articles by Hatem Soliman, MD
94 Treatment Persistence and Dose Modifications in US Patients With HR+/HER2−, Node-Positive, Early Breast Cancer Treated With Adjuvant Abemaciclib
ByHatem Soliman, MD,Susan Dent, MD,Astra M. Liepa,Victoria J. Stefaniak,Minxuan Huang,Tomoko Sugihara,Katheryn Moreira,Kathryn Hudson,Matthew P. Goetz, MD 
49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval
ByKatheryn Moreira,Kathryn Hudson,Wambui Gathirua-Mwangi,Zhanglin Lin Cui,Madeline Richey,Brenda Grimes,Jingru Wang,Astra Liepa,Erich Brechtelsbauer,Raisa Volodarsky,Hatem Soliman, MD 
20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer
ByErika P. Hamilton, MD,Lajos Pusztai, MD, DPhil,Hatem Soliman, MD,Sara A. Hurvitz, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Priya Marreddy,Tarek Sahmoud, MD,Nuhad Ibrahim, MD 
Propelling Immunotherapy Combinations Into the Clinic
ByNishan Tchekmedyian, MD,Jhanelle E. Gray, MD,Benjamin C. Creelan, MD,Alberto A. Chiappori, MD,Amer A. Beg, PhD,Hatem Soliman, MD,Bradford A. Perez, MD,Scott J. Antonia, MD, PhD This review summarizes promising new targets and immunotherapy combination strategies currently under clinical development.